350 related articles for article (PubMed ID: 17949799)
1. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
Alberts DS; Liu PY; Wilczynski SP; Clouser MC; Lopez AM; Michelin DP; Lanzotti VJ; Markman M;
Gynecol Oncol; 2008 Jan; 108(1):90-4. PubMed ID: 17949799
[TBL] [Abstract][Full Text] [Related]
2. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
[TBL] [Abstract][Full Text] [Related]
3. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.
Markman M; Moon J; Wilczynski S; Lopez AM; Rowland KM; Michelin DP; Lanzotti VJ; Anderson GL; Alberts DS
Gynecol Oncol; 2010 Mar; 116(3):323-5. PubMed ID: 20044128
[TBL] [Abstract][Full Text] [Related]
4. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
[TBL] [Abstract][Full Text] [Related]
5. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A
J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.
Bafaloukos D; Linardou H; Aravantinos G; Papadimitriou C; Bamias A; Fountzilas G; Kalofonos HP; Kosmidis P; Timotheadou E; Makatsoris T; Samantas E; Briasoulis E; Christodoulou C; Papakostas P; Pectasides D; Dimopoulos AM
BMC Med; 2010 Jan; 8():3. PubMed ID: 20055981
[TBL] [Abstract][Full Text] [Related]
8. Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.
Holloway RW; Grendys EC; Lefebvre P; Vekeman F; McMeekin S
Oncologist; 2010; 15(10):1073-82. PubMed ID: 20930103
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Gladieff L; Ferrero A; De Rauglaudre G; Brown C; Vasey P; Reinthaller A; Pujade-Lauraine E; Reed N; Lorusso D; Siena S; Helland H; Elit L; Mahner S
Ann Oncol; 2012 May; 23(5):1185-1189. PubMed ID: 21976386
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
Power P; Stuart G; Oza A; Provencher D; Bentley JR; Miller WH; Pouliot JF
Gynecol Oncol; 2009 Sep; 114(3):410-4. PubMed ID: 19520420
[TBL] [Abstract][Full Text] [Related]
11. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Mahner S; Meier W; du Bois A; Brown C; Lorusso D; Dell'Anna T; Cretin J; Havsteen H; Bessette P; Zeimet AG; Vergote I; Vasey P; Pujade-Lauraine E; Gladieff L; Ferrero A
Eur J Cancer; 2015 Feb; 51(3):352-8. PubMed ID: 25534295
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.
Landrum LM; Brady WE; Armstrong DK; Moore KN; DiSilvestro PA; O'Malley DM; Tenney ME; Rose PG; Fracasso PM
Gynecol Oncol; 2016 Feb; 140(2):204-9. PubMed ID: 26616225
[TBL] [Abstract][Full Text] [Related]
15. [Safety and efficacy of pegylated liposomal Doxorubicin and Carboplatin on platinum-sensitive recurrent epithelial ovarian cancer].
Nishio S; Ushijima K; Shimizu T; Tachibana T; Nasu H; Aiko K; Kawano R; Kurokawa Y; Sumino Y; Yokomine M; Takemoto S; Kamura T
Gan To Kagaku Ryoho; 2013 Dec; 40(13):2539-43. PubMed ID: 24335366
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer.
Rapoport BL; Vorobiof DA; Slabber C; Alberts AS; Hlophe HS; Mohammed C
Int J Gynecol Cancer; 2009 Aug; 19(6):1137-41. PubMed ID: 19820382
[TBL] [Abstract][Full Text] [Related]
17. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.
Vergote I; Finkler NJ; Hall JB; Melnyk O; Edwards RP; Jones M; Keck JG; Meng L; Brown GL; Rankin EM; Burke JJ; Boccia RV; Runowicz CD; Rose PG
Int J Gynecol Cancer; 2010 Jul; 20(5):772-80. PubMed ID: 20973267
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group.
Lai CH; Vallikad E; Lin H; Yang LY; Jung SM; Liu HE; Ou YC; Chou HH; Lin CT; Huang HJ; Huang KG; Qiu J; Hung YC; Wu TI; Chang WY; Tan KT; Lin CY; Chao A; Chang CJ
J Gynecol Oncol; 2020 Jan; 31(1):e5. PubMed ID: 31788995
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
Kurtz JE; Kaminsky MC; Floquet A; Veillard AS; Kimmig R; Dorum A; Elit L; Buck M; Petru E; Reed N; Scambia G; Varsellona N; Brown C; Pujade-Lauraine E;
Ann Oncol; 2011 Nov; 22(11):2417-2423. PubMed ID: 21402619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]